Ariad Pharmaceuticals announces the issuance of U.S. patent on brigatinib, ALK inhibitor
Wednesday, April 22, 2015
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the issuance of its first U.S. patent on brigatinib, ARIAD's investigational ALK inhibitor. The United States Patent and Trademark Office granted U.S. Patent No. 9,012,462 under the title, "Phosphorous Derivatives as Kinase Inhibitors." The patent provides composition-of-matter protection through at least December 30, 2030 for ARIAD's investigational ALK inhibitor, brigatinib. Additional patent applications covering brigatinib are pending in the U.S. and in other countries.
"This has been an important week for brigatinib, beginning with ARIAD's presentation of preclinical and clinical data on brigatinib and the unveiling of its novel design features at the American Association for Cancer Research (AACR) Annual Meeting. The issuance of the initial brigatinib patent highlights the innovative design of the brigatinib molecule," stated Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. "We continue to enroll patients in our Phase 2 ALTA trial and look forward to sharing the first data from that clinical trial later this year."
twst.com
